Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

This study is testing a combination of SBRT (stereotactic body radiation therapy — highly precise, high-dose radiation), the immunotherapy drug tislelizumab, and a targeted therapy called regorafenib for people with liver cancer (HCC) that cannot be surgically removed or has spread to a small number of sites. **You may be eligible if...** - You are 18 or older - You have confirmed liver cancer (HCC) that is locally advanced or has spread to 5 or fewer sites in 3 or fewer organs - You have not had brain metastases - You have good performance status (ECOG 0–1) - You have adequate liver function **You may NOT be eligible if...** - Your cancer has spread to the brain - You have had prior immunotherapy or regorafenib - You have serious autoimmune disease - You have very poor liver function (Child-Pugh C) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.